Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Amylin analogue peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Selective amylin receptor agonism.
Evidence and critical reading
Reported scientific and empirical uses
Reported weight management
Investigational selective amylin agonist; a commercial vial is not the trial medicine.
Human evidence
Phase 2 randomized trial in 263 adults reported weight reduction over 48 weeks. The investigational trial formulation does not validate supplier vials.
Preclinical evidence
Clinical evidence is more relevant than animal inference for the studied indication.
Critical reading and limitations
A 263-adult, 48-week randomized phase II trial showed weight reduction, not approval or stack safety.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
1 / 3 / 6 / 9 mg · Different study arms; some with escalation
- Frequency
- Weekly
- Duration
- 48 weeks
- Route
- Subcutaneous
- Context
- Phase II; some arms escalated to 9 mg. Not a titration table.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID41207310 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Gastrointestinal adverse events and trial selection limit generalizability; long-term and combination safety require separate evaluation.
GI events, participant selection and duration bound benefit/risk conclusions.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
NCT06230523 · A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightRegistry status: CompletedLast update posted: June 24, 2026Query verification: October 16, 2026
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Eloralintide · 18 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07215559 · A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesRegistry status: Active, not recruitingLast update posted: October 9, 2026Query verification: October 16, 2026
NCT07369011 · A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightRegistry status: RecruitingLast update posted: October 8, 2026Query verification: October 16, 2026
NCT07353931 · Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightRegistry status: RecruitingLast update posted: October 8, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID41207310
Billings LK, Hsia S, Bays H, Tidemann-Miller B, O'Hagan J, Tham LS, Butler A, Kazda C, Mather KJ, Coskun T.
October 16, 2026